Last reviewed · How we verify

NCT03843021

Ventricular Assist Device (VAD) Infection Prevention Survey

Completed Last updated 14 July 2023
What this trial tests

trial testing VAD Infection Prevention Survey in Heart Failure in 208 participants. Completed in 23 December 2022.

Timeline
29 May 2019
Primary endpoint
23 December 2022
23 December 2022

Quick facts

Lead sponsorUniversity of Michigan
StatusCompleted
Study typeOBSERVATIONAL
Enrollment208
Start date29 May 2019
Primary completion23 December 2022
Estimated completion23 December 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Michigan

Who can join

18 and older, any sex, with Heart Failure or Healthcare Associated Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Annually, more than 250,000 patients in the U.S. with end-stage heart failure stand to benefit from ventricular assist device (VAD) therapy. 60% of patients develop a healthcare-associated infection (HAI) within 90-days of implantation. The investigators long term goal is to develop and subsequently promote wide-scale adoption of evidence-based HAI prevention practices following durable VAD implantation. This will be done by addressing the following aims: Aim 1. Identify determinants of center-level variability in HAI rates. Aim 2. Develop a comprehensive understanding of barriers and facilitators for achieving low center HAI rates. Aim 3. Develop, iteratively enhance, and disseminate a best practices toolkit for preventing HAIs that accommodates various center contexts. The investigators will use a focused survey of U.S. VAD centers to identify determinants of center variation in 90-day HAI rates: * Process Factors (e.g., intranasal mupirocin), * Provider Factors (e.g., surgeon technique), * Device Factors (e.g., centrifugal vs. axial), * Center Factors (e.g., provider communication). Understanding the barriers and facilitators within individual centers for maximizing adoption of prevention measures would serve as the foundation for targeted improvement strategies. Without this knowledge, evidence-based, action-oriented recommendations will have limited local adoption and ultimately effectiveness in preventing HAIs after VAD implantation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other University of Michigan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03843021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing